Fazamorexant

法赞雷生

Report date: 2026/05/21 20:00:22
NME

Base Information

Drug NameFazamorexant
Drug Alias Name孟平YZJ-1139YZJ1139
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionOrexin receptor type 1 antagonistsOrexin receptor type 2 antagonists
TargetsOrexin receptor type 1Orexin receptor type 2
Therapy Area/IndicationsRenal InsufficiencySleep Initiation and Maintenance DisordersCentral Nervous System Diseases +[4] 
Global Approved IndicationsSleep Initiation and Maintenance Disorders
Approved Indications in ChinaSleep Initiation and Maintenance Disorders
Original Approved Country/TerritoryMainland China
Original Approved Date2026/05/19
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesYangtze River Pharmaceutical (Group) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Haiyan Pharmaceutical Technology Co LtdJiangsu Haian Pharmaceutical Co Ltd
Inactive CompaniesYangtze River Pharmaceutical (Group) Co LtdYangtze River Pharmaceutical Group Jiangsu Haici Biological Pharmaceutical Co Ltd
Active IndicationsRenal InsufficiencySleep Initiation and Maintenance DisordersCentral Nervous System Diseases +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A